Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

Core Insights - Acumen Pharmaceuticals is set to present new findings at the Alzheimer's Association International Conference (AAIC®) 2025, focusing on cost savings from using pTau217 as a screening tool in its Phase 2 ALTITUDE-AD trial of sabirnetug for Alzheimer's disease [1][2] - The company emphasizes the significance of combining biomarker-driven screening with targeted therapeutics to enhance clinical trial designs and drug development for Alzheimer's disease [2] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing sabirnetug (ACU193), a humanized monoclonal antibody targeting soluble amyloid beta oligomers (AβOs), which are linked to Alzheimer's disease [3][5] - Sabirnetug has received Fast Track designation from the U.S. FDA for treating early Alzheimer's disease and is currently in a Phase 2 study [3][7] ALTITUDE-AD Trial - The ALTITUDE-AD trial, initiated in 2024, is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's disease patients [4] - The trial has enrolled 542 participants across multiple sites in the U.S., Canada, the EU, and the UK [4] Presentation Details - Acumen's presentations at AAIC will cover the cost savings analysis of pTau217 in the ALTITUDE-AD trial and the selectivity of sabirnetug for Aβ oligomers compared to other treatments like lecanemab and aducanumab [2][6]